ÂÜÀòÂÒÂ×

Beth Chang has extensive work experience in the medical field, with a focus on clinical development, medical affairs, and pipeline programs. Beth is currently serving as the Senior Medical Director at GRAIL, Inc., where they provide clinical and translational leadership for the Clinical Development - Companion Diagnostics (CDx) team. In this role, they oversee a team of Medical Directors and Clinical Scientists, develops the overall vision and strategy for the GRAIL Oncology product portfolio, and leads the design and implementation of NGS-based assays for Oncology diagnostic tests. Beth also drives the incorporation of clinical biomarker strategies, leads clinical evidence generation plans and strategies, and engages with key stakeholders to drive the successful adoption of GRAIL products.

Prior to their current role at GRAIL, Beth served as the Medical Director for the Circulating Cell-free Genome Atlas (CCGA) Study, which enabled the successful commercial launch of Galleri, a breakthrough early cancer detection test. Beth also served as the Medical Director for the STRIVE study, a large-scale cohort study to validate the Galleri test.

Before GRAIL, Beth held senior positions at Exelixis, Gilead Sciences, Biogen Idec, and Amunix. In their role as Senior Director of Clinical Science at Exelixis, they contributed to the development of clinical strategies. At Gilead Sciences, they served as an Associate Medical Director, focusing on global medical affairs in oncology. Beth also worked as a Senior Manager-Medical Affairs Lead at Biogen Idec, with a focus on pipeline programs related to hemophilia, sickle cell disease, and thalassemia.

Beth began their career at Amunix, where they served as an Associate Director. Their responsibilities in this role are not specified in the provided information.

Beth Chang received their High School Diploma from National Experimental High School from 1992 to 1995. Beth then went on attend National Taiwan University from 1995 to 1999, earning a B.S. in Chemistry. Beth continued their education at the University of Wisconsin-Madison from 2000 to 2006, where they obtained their Ph.D. in Pharmacology. Beth further pursued their studies at Stanford University, completing a Post-doctoral Certificate in Pathology and Oncology from 2006 to 2010.